MABS432MI
MilliporeSigma™ anti-MEK1 Clone: 6B7.1,
Manufacturer: MilliporeSigma™
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | MABS432MI-Each-of-1 | In Stock | ₹ 40,292.08 |
MABS432MI - Each of 1
In Stock
Quantity
1
Base Price: ₹ 40,292.08
GST (18%): ₹ 7,252.574
Total Price: ₹ 47,544.654
Antigen
MEK1
Classification
Monoclonal
Conjugate
Unconjugated
Gene Accession No.
Q02750
Host Species
Mouse
Purification Method
Protein G purified
Regulatory Status
RUO
Primary or Secondary
Primary
Test Specificity
Expected to react with both the MKK1a and MKK1b spliced isoforms.
Content And Storage
2°C to 8°C for one year from date of shipment
Isotype
IgG2a κ
Applications
Western Blot
Clone
6B7.1
Formulation
Purified mouse monoclonal IgG2aκ antibody in buffer containing 0.1M Tris-Glycine (pH 7.4), 150mM NaCl with 0.05% sodium azide.
Gene Symbols
MAP2K1, MEK1, PRKMK1
Immunogen
GST-tagged recombinant protein corresponding to the C-terminal region of human MEK1.
Quantity
100 μg
Research Discipline
Signaling
Gene ID (Entrez)
NP_002746
Target Species
Human
Form
Purified
Related Products
Description
- Specifically detects MEK1 Clone: 6B7.1 in Human samples, and it is validated for Western Blotting Dual specificity mitogen-activated protein kinase kinase 1 (EC 2.7.12.2; UniProt Q02750; also known as ERK activator kinase 1, MAP kinase kinase 1, MAPK/ERK kinase 1, MAPKK 1, MEK 1, MKK1) is encoded by the MAP2K1 (also known as CFC3, MAPKK1, MEK1, MKK1, PRKMK1) gene (Gene ID 5604) in human
- MEK1 and the related MEK2 are dual specificity kinases of the MAP2K/STE7 kinase family
- MEK1 and MEK2 share a high degree of sequence homology and perform similar functions
- Upon activation by RAF, MEK1/2 catalyze the dual phosphorylation of threonine and tyrosine residues on ERK (MAPK) within a specific Thr-Glu-Tyr sequence at codons 202 to 204
- This locks the kinase domain of MAPK into a catalytically competent conformation, ultimately leading to nuclear signals that regulate cellular growth and proliferation
- MEK1/2 mutations have been reported to be associated with cardiofaciocutaneous syndrome 3 (CFC3) and cancers, including lung cancer, colorectal cancer, and melanomas.